Our view: Setbacks are costly but biotech industry copes

You are here: Home > Biotech > Current Article

Our view: Setbacks are costly but biotech industry copes

By Editorial board and Henry Dubroff / Friday, July 19th, 2019 / Comments Off on Our view: Setbacks are costly but biotech industry copes

Amid a boom in the biotech industry in the Conejo Valley, comes a reminder that drug discovery is expensive and not risk-free. On July 11, Thousand Oaks-based Amgen and partners Novartis, another pharmaceuticals giant, and the Banner Alzheimer’s Institute abruptly halted clinical trials for CNP520, a drug that had shown promise for the prevention of…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.